Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is advancing its clinical-stage pipeline with a focus on one-time gene therapies targeting neurodegenerative diseases, specifically through its lead candidate, PBFT02. The company's amended protocol for trial design presents an opportunity for earlier intervention, potentially enhancing the treatment's efficacy, while the anticipation of regulatory alignment for accelerated approval could shorten trial timelines. Furthermore, encouraging biomarker data and the strategic enrollment of patients in Cohort 3 may accelerate overall progress, positioning Passage Bio favorably in the competitive landscape within the genetic medicines sector.

Bears say

Passage Bio Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays in clinical timelines and emerging safety signals associated with its early gene therapy programs. The complexity of manufacturing AAV-based gene therapy products presents additional challenges, particularly in ensuring sufficient production capacity, which could lead to constrained financial forecasts. Additionally, historical setbacks in the gene therapy sector highlight the possibility of unforeseen safety issues that may negatively impact market sentiment towards Passage Bio.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.